Soligenix- Warrants (07/12/2021) Overview
Latest ROE for Soligenix- Warrants (07/12/2021): -84.99% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-84.99%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Soligenix- Warrants (07/12/2021) posts a ROE of -84.99%. That is below the Healthcare sector average of 21.67%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 21.67% is typical. Soligenix- Warrants (07/12/2021)'s -84.99% is lower that level. That is roughly 492.2% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Soligenix- Warrants (07/12/2021)'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -84.99%; use YoY and peer views to separate noise from signal.
Context for SNGXW's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 21.67%), and (3) consistency with growth and profitability. This page covers the first two; Soligenix- Warrants (07/12/2021)'s other metric pages and overview cover the third.
Judging Soligenix- Warrants (07/12/2021) against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -84.99% here, then scan peer and history charts to see if the gap is persistent.
